Environmental Exposures, Genetics, and Exhaled Nitric Oxide in Pediatric Asthma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Asthma is one of the most common childhood diseases. It is chronic and often severely disabling. The amount of nitric oxide that is exhaled while breathing increases with airway inflammation, a symptom of asthma. This study will examine the results from a previous study, the Cincinnati Asthma Prevention (CAP) study, to evaluate the effects of environmental and genetic factors on exhaled nitric oxide (eNO) levels and to determine the relationship between eNO and asthma severity.
| Condition |
|---|
|
Asthma |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Environmental Exposures, NOS Genes, and Exhaled Nitric Oxide in Pediatric Asthma |
- Effects of environmental and genetic factors on exhaled nitric oxide (eNO) levels and the relationship between eNO and asthma severity [ Time Frame: Measured through the use of data previously collected in the Cincinnati Asthma Prevention (CAP) study ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood and urine
| Enrollment: | 225 |
| Study Start Date: | July 2006 |
| Study Completion Date: | June 2008 |
Nitric oxide is a naturally occurring gas that plays a role in many body functions. Levels of eNO increase with airway inflammation, a symptom of asthma. Researchers have proposed using eNO as a noninvasive measure to guide physicians in the treatment and medical management of asthma in children. However, more information about eNO is needed before this can happen. This study will perform a secondary analysis of the results from its parent study, the CAP study, which evaluated the effectiveness of preventing asthma in children who had been exposed to environmental tobacco smoke.
This study will not enroll any new participants. Previously collected data from the CAP study will be reevaluated in this study to determine the longitudinal effects of environmental and genetic factors on eNO levels. In addition, the data will be evaluated to determine the relationship between eNO levels and asthma severity. No new data will be collected in this study.
Eligibility| Ages Eligible for Study: | 6 Years to 12 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Cincinnati area children with asthma
Inclusion Criteria:
- Participated in the Cincinnati Asthma Prevention Study
- Diagnosis of asthma
- Lives with someone that smokes at least 5 cigarettes a day
Exclusion Criteria:
- No additional neuromuscular or respiratory disorder that may interfere with safe participation in the parent study
- Does not have electricity
- Plans to move within 1 year of entry into the parent study
Contacts and Locations| United States, Ohio | |
| Cincinnati Children's Hospital Medical Center | |
| Cincinnati, Ohio, United States, 45229-3039 | |
| Principal Investigator: | Adam J. Spanier, MD, MPH | Children's Hospital Medical Center, Cincinnati |
More Information
Publications:
| Responsible Party: | Adam Spanier, Cincinnati Children's Hospital Medical Center |
| ClinicalTrials.gov Identifier: | NCT00395096 History of Changes |
| Other Study ID Numbers: | 1354, R21 HL083145-01A1 |
| Study First Received: | October 31, 2006 |
| Last Updated: | February 17, 2009 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Heart, Lung, and Blood Institute (NHLBI):
|
Exhaled Nitric Oxide Asthma Tobacco Smoke Allergen |
Additional relevant MeSH terms:
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Nitric Oxide Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Pharmacologic Actions Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Endothelium-Dependent Relaxing Factors Vasodilator Agents Cardiovascular Agents Protective Agents |
ClinicalTrials.gov processed this record on May 19, 2013